FDA Approves First Next-Generation DNA Sequencing Platforms

Illumina’s MiSeqDx instrument and MiSeqDx Universal Kit, granted de novo approval, allow clinicians to “develop and validate sequencing of any part of a patient’s genome,” FDA says.

High-throughput, next-generation DNA sequencing (NGS) devices received their first regulatory clearances from FDA Nov. 19 when the agency granted de novo approvals to two nondisease-specific diagnostic platforms made by Illumina Inc.

Illumina’s MiSeqDxPlatform instrumentation and MiSeqDx Universal Kit 1.0 allow clinicians to “develop and validate sequencing of any part of a...

More from Archive

More from Medtech Insight